Ocular Therapeutix, Inc. (OCUL)
10.72
-0.18
(-1.70%)
USD |
NASDAQ |
Sep 03, 13:34
Ocular Therapeutix Cash from Investing (Quarterly) : -3.367M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.367M |
| March 31, 2026 | -4.662M |
| December 31, 2025 | -2.839M |
| September 30, 2025 | -5.993M |
| June 30, 2025 | -1.115M |
| March 31, 2025 | -1.933M |
| December 31, 2024 | -0.202M |
| September 30, 2024 | -0.089M |
| June 30, 2024 | -0.742M |
| March 31, 2024 | -0.255M |
| December 31, 2023 | -0.459M |
| September 30, 2023 | -0.259M |
| June 30, 2023 | -1.99M |
| March 31, 2023 | -3.379M |
| December 31, 2022 | -2.15M |
| September 30, 2022 | -0.794M |
| June 30, 2022 | -0.495M |
| March 31, 2022 | -0.276M |
| December 31, 2021 | -0.631M |
| September 30, 2021 | -0.276M |
| June 30, 2021 | -0.129M |
| March 31, 2021 | -0.158M |
| December 31, 2020 | -0.253M |
| September 30, 2020 | -0.214M |
| June 30, 2020 | -0.125M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.249M |
| December 31, 2019 | -0.601M |
| September 30, 2019 | -0.419M |
| June 30, 2019 | -0.493M |
| March 31, 2019 | -0.725M |
| December 31, 2018 | -0.479M |
| September 30, 2018 | -0.473M |
| June 30, 2018 | -0.556M |
| March 31, 2018 | -0.381M |
| December 31, 2017 | -0.45M |
| September 30, 2017 | 0.969M |
| June 30, 2017 | 18.70M |
| March 31, 2017 | 7.846M |
| December 31, 2016 | -12.38M |
| September 30, 2016 | 11.32M |
| June 30, 2016 | 11.76M |
| March 31, 2016 | 24.87M |
| December 31, 2015 | -2.086M |
| September 30, 2015 | -27.59M |
| June 30, 2015 | 8.958M |
| March 31, 2015 | -17.85M |
| December 31, 2014 | -37.77M |
| September 30, 2014 | -0.274M |
| June 30, 2014 | -0.248M |
| March 31, 2014 | -0.297M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| EyePoint, Inc. | 75.10M |
| LENZ Therapeutics, Inc. | 37.75M |
| Merck & Co., Inc. | -5.602B |
| Theravance Biopharma, Inc. | -60.40M |
| ANI Pharmaceuticals, Inc. | -3.054M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -67.27M |
| Cash from Financing (Quarterly) | 2.581M |
| Free Cash Flow | -255.10M |
| Free Cash Flow Per Share (Quarterly) | -0.314 |
| Free Cash Flow to Equity (Quarterly) | -70.56M |
| Free Cash Flow to Firm (Quarterly) | -67.85M |
| Free Cash Flow Yield | -11.13% |